# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Leerink Partners analyst Faisal Khurshid initiates coverage on Galapagos (NASDAQ:GLPG) with a Market Perform rating and anno...
Galapagos stock rises as EcoR1 Capital discloses a 9.9% stake and plans to engage on business and governance. Investor sees sha...
Galapagos NV announced that the U.S. Food and Drug Administration (FDA) has cleared Galapagos' Investigational New Drug (IN...
Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 16 August 2024 from FMR LLC, w...
FDA approves Adaptimmune Therapeutics' Tecelra for unresectable or metastatic synovial sarcoma, a rare cancer near large jo...